Safer, more effective ALL therapies still needed
Despite ALL treatment progress, patients still need safer, more effective options Novel agents have transformed outcomes for patients with relapsed or refractory acute
SBBC
Leukemia
Acute Lymphoblastic Leukemia
Meetings / Conferences
News
SBBC
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Meeting News
A 2025 lymphoma snapshot from Julie Vose, MD, MBA
Dr. Vose will be speaking at 12:30 pm Central time on November 20, 2025, during SBBC. At 12:55 pm Central time, attendees can
Multiple Myeloma
SOHO Insider Podcast
Does the future of myeloma treatment belong to trispecific antibodies?
In this SOHO Insider podcast, Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Niels W C
Lymphoma
Indolent B-Cell Lymphomas
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval
Past Issues
SOHO Insider 2025 print issue November/December
The SOHO Insider 2025 print issue November/December features an article on a joint pilot R/R CLL/SLL program between SOHO and the Medical Learning
Leukemia News
FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML
The US Food and Drug Administration has approved the menin inhibitor ziftomenib for treatment of relapsed or refractory NMP1-mutated acute myeloid leukemia in
Multiple Myeloma
FDA grants 510(k) clearance to multiple myeloma diagnostic platform
The US Food and Drug Administration (FDA) granted 510(k) clearance to the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay, a first-of-its-kind automated platform for
SITC 2025
Multiple Myeloma
IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma
In a first-in-human study, IDP-023 demonstrated a promising safety and efficacy profile in patients with relapsed or refractory multiple myeloma, according to findings
SITC 2025
Leukemia
Acute Lymphoblastic Leukemia
News
Natural killer T-cells show promise for ‘off-the-shelf’ cancer immunotherapy for NHL, ALL
Allogeneic natural killer T cells (NKTs) expressing CD19-specific chimeric antigen receptors (CARs) are well tolerated and can mediate objective responses in non-Hodgkin’s lymphoma
Multiple Myeloma
Video Interviews
Dr. Mateos discusses blenrep/DREAMM-7 trial
Dr. Mateos was the lead investigator on the trial, which investigated belantamab mafodotin (blenrep) with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib